We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rifaximin in Fatty Liver Disease (RiFL)

This study has been terminated.
(Review of primary endpoint data by study Investigators concluded no further patients required.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01355575
First Posted: May 18, 2011
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Health Service, United Kingdom
Information provided by (Responsible Party):
Imperial College London
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2012
  Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)